

UC Davis

UC Davis Previously Published Works

Title

Attention/Deficit Hyperactivity Disorder in Adolescent and Young Adult Males With Fragile X Syndrome.

Permalink

<https://escholarship.org/uc/item/2vw2n0pj>

Journal

American Journal on Intellectual and Developmental Disabilities, 127(3)

ISSN

1944-7515

Authors

Klusek, Jessica
O'Connor, Shannon L
Hickey, Alexandra
et al.

Publication Date

2022-05-01

DOI

10.1352/1944-7558-127.3.213

Peer reviewed



HHS Public Access

Author manuscript

Am J Intellect Dev Disabil. Author manuscript; available in PMC 2023 May 01.

Published in final edited form as:

Am J Intellect Dev Disabil. 2022 May 01; 127(3): 213–230. doi:10.1352/1944-7558-127.3.213.

ATTENTION/DEFICIT HYPERACTIVITY DISORDER IN ADOLESCENT AND YOUNG ADULT MALES WITH FRAGILE X SYNDROME

Jessica Klusek, Ph.D.,

University of South Carolina, Department of Communication Sciences and Disorders, 1705 College Street, Columbia, SC, 29208, USA

Shannon L. O'Connor, M.A.,

Department of Psychology, University of South Carolina, Columbia, South Carolina, 29208, USA.

Alexandra Hickey, B.S.,

Department of Communication Sciences and Disorders, University of South Carolina, Columbia, South Carolina, 29208, USA.

Kimberly J. Hills, Ph.D.,

Department of Psychology, University of South Carolina, Columbia, South Carolina, 29208, USA.

Leonard Abbeduto, Ph.D.,

Department of Psychiatry and Behavioral Sciences and MIND Institute, University of California Davis Health, Sacramento, CA 95817, USA

Jane E. Roberts, Ph.D.

Department of Psychology, University of South Carolina, Columbia, South Carolina, 29208, USA.

Abstract

This study characterized the rates of rates of attention-deficit/hyperactivity disorder (ADHD) in adolescent and young adult males with fragile X syndrome (FXS) using a multi-method approach integrating a DSM-based parent interview (Children's Interview for Psychiatric Syndromes; P-ChIPS, Fristad et al., 1998) and a parent rating scale (Child Behavior Checklist; CBCL, Achenbach, 2001). Thirty-one males with FXS, aged 16-24 years, participated. Forty-two percent met DSM-5 criteria for ADHD and 35% exceeded the CBCL cut-offs. Agreement between the two classification methods was fair ($\kappa=0.38$). Autism symptom severity and nonverbal cognitive ability did not predict ADHD diagnoses/symptoms. Results show high rates of ADHD in males with FXS during late adolescence and young adulthood, which are not accounted for by impaired nonverbal cognitive skills or autism symptom severity. DSM-based ADHD-specific scales are recommended over broadband symptom scales to improve accurate identification.

Keywords

ADHD; intellectual disability; autism; FMR1

Corresponding Author: **Jessica Klusek, Ph.D.**, Klusek@mailbox.sc.edu, University of South Carolina, Department of Communication Sciences and Disorders, 1705 College Street, Columbia, SC, 29208, USA.

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder marked by symptoms of hyperactivity, inattention, impulsivity and executive functioning weaknesses (American Psychiatric Association, 2013). ADHD is the most commonly diagnosed behavioral disorder in children, with rates in the general population ranging from 9-11% during childhood to about 4% in adulthood (Danielson et al., 2018; Kessler et al., 2006). Diagnoses of ADHD are nearly three times more common in males than females and are associated with a high degree of cooccurrence with other mental, emotional, and behavioral disorders (Danielson et al., 2018; Reale et al., 2017). The burden of ADHD is significant and there is great value in research aimed at understanding the nature and course of ADHD. Adverse outcomes associated with ADHD include higher rates of injury, social difficulties, and reduced educational and vocational achievement (Harpin et al., 2016; Hinshaw et al., 2012; Kuriyan et al., 2013; Loe & Feldman, 2007). For the majority of affected individuals, ADHD symptoms persist into adulthood and are associated with psychiatric comorbidity, substance abuse, criminal activity, failed relationships and underemployment (Barkley et al., 2004; Biederman et al., 2010; Margherio et al., 2020; Molina et al., 2018).

Although the precise causal mechanism of ADHD is not clear, the evidence supports a strong genetic component (Li et al., 2014; Stergiakouli et al., 2012). Recent discoveries have identified clear genetic overlaps of ADHD to both autism spectrum disorder (ASD) and intellectual disability, and thus, investigations into the interface between ADHD, ASD, and intellectual disability can advance the field (Faraone et al., 2017; Ghirardi et al., 2018; May et al., 2018; Pinto et al., 2016; Stergiakouli et al., 2017). Fragile X syndrome (FXS) may represent a useful genetic model in this regard; FXS is a monogenetic disorder that is the most common known single-gene cause of ASD and the leading inherited cause of intellectual disability (Vissers et al., 2016; Waye & Cheng, 2018). FXS is found in about 1:7,000 males and 1:10,000 females (Hunter et al., 2014) and involves a trinucleotide repeat expansion on the *FMR1* gene. FXS is associated with reduced Fragile X Mental Retardation Protein (FMRP), which is involved in typical brain maturation (Siegel et al., 2017; Zhang et al., 2017). The phenotype of males with FXS is marked by nearly universal intellectual disability and about cooccurring ASD observed in approximately 60% of males (García-Nonell et al., 2008; Harris et al., 2008; Klusek, Martin, & Losh, 2014).

ADHD is also a common cooccurring condition associated with FXS, with reported rates in children with FXS ranging from 35-93%, as reflected in Table 1 (Backes et al., 2000; Bailey et al., 2008; Bregman et al., 1988; Freund et al., 1993; Hatton et al., 2002; Sullivan et al., 2006; Thurman et al., 2014). Consistent with the profile of ADHD in the general community, ADHD in FXS emerges during childhood (Grefer et al., 2016) and is more likely to affect males than females (Newman et al., 2015; Wheeler et al., 2014). Across studies, the rates of ADHD symptoms and diagnoses in males with FXS are consistently higher than in the general population without FXS and also higher than those with non-specific intellectual disability or other known genetic syndromes (Baumgardner et al., 1995; Reilly et al., 2015). Severity of intellectual impairment does not appear to be associated with the presence or severity of ADHD (Newman et al., 2015); however, this has not been studied extensively. In studies that have examined the relationship of ASD to ADHD in FXS, findings are inconsistent with some reports suggesting that elevated ASD severity is linked

with ADHD features (Sullivan et al., 2006), whereas others suggest that ADHD symptoms are similar across individuals with FXS with or without comorbid ASD (Hatton et al., 2002; Newman et al., 2015). In a study that included a group of male children with FXS contrasted to a chronological age, IQ and ASD-severity matched group with non-syndromic ASD, ADHD symptoms were significantly higher in the group with FXS (Thurman et al., 2014). Inattention, rather than hyperactivity, appears to be the most prominent feature of ADHD in FXS, with one investigation of 63 7-13 year-old children with FXS suggesting that 32% exhibited a predominately inattentive ADHD presentation (ADHD-I), 7% exhibited a hyperactive/impulsive presentation (ADHD-H), and 15% exhibited a combined presentation (ADHD-C) (Sullivan et al., 2006). Overall, the evidence supports FXS as a saturated model for ADHD risk that integrates elevated risk for ADHD within the context of intellectual disability and ASD.

The presence of ADHD in males with FXS is associated with significant impairment including reduced prosocial behavior and social functioning (Chromik et al., 2019; Scerif et al., 2012) as well as increased family burden (Wheeler et al., 2014). The presence of multiple cooccurring conditions within FXS is associated with more significant impairment, with intellectual disability, attention problems, hyperactivity, and anxiety constituting the most common cluster of comorbid disorders in males with FXS (Bailey et al., 2008). Treatment for ADHD in males with FXS primarily involves medication, with stimulant medication reported as moderately to highly effective (Berry-Kravis et al., 2012; Hagerman et al., 1988; Roberts et al., 2011b), and results of a national survey suggest ~30% of people with FXS use stimulants (Laxman et al., 2018). However, evidence suggests that the attention and thought problems associated with ADHD do not differ between children with FXS taking medication and those not being treated, thereby raising questions about medication efficacy (Hatton et al., 2002). Obtaining a better understanding of the targets and benefits of medication is important because pharmaceutical treatment for ADHD is a common approach in FXS. These efforts also have implications for clinical trials in which ADHD-related manifestations of FXS represent common behavioral targets (Berry-Kravis et al., 2013; Budimirovic et al., 2017).

Although there is an emerging body of research that provides insights into ADHD in FXS, there are a number of limitations of this work. First, several studies used samples that were highly heterogeneous including a very broad age range (Gabis et al., 2011; Haessler et al., 2016), inclusion of participants with the *FMR1* premutation (i.e., “carriers” of fragile X) together with those having the full mutation (Newman et al., 2015), and failure to account for ASD (Frolli et al., 2015; Pegoraro et al., 2014). In addition, the focus of research to date has largely been on young children with little work specifically targeting adolescents and young adults. It is unclear from prior research whether individuals with FXS continue to experience high rates of ADHD symptoms into late adolescence and young adulthood. Although some studies suggest a general reduction of symptoms across age (Gabis et al., 2011; Haessler et al., 2016; Wheeler et al., 2014), other reports suggest that the symptoms of ADHD do not abate from early childhood into adolescence (Newman et al., 2015; Thurman et al., 2014).

A final limitation of the extant literature is that studies to date have not used the revised DSM-5 criteria, and there is a clear over-reliance on broad-based measurement tools that detect a wide range of different symptoms and are not specifically targeted at measuring ADHD (Bailey et al., 2008; Grefer et al., 2016). Although there is value in broad-based measures because they allow for easy detection and screen for a wide variety of disorders, they often lack specificity for individuals who have comorbid disabilities such as ASD (Pandolfi et al., 2012). Utilizing ADHD-specific scales and the most recent DSM-based measures to characterize ADHD in a carefully selected sample is necessary to advance our understanding of the prevalence of ADHD in males with FXS. This work is critical because ADHD in FXS is clearly pervasive and interferes with optimal functioning, and documentation of comorbidities within FXS is essential to directing effective treatment. However, this research is complex given the presence of co-occurring conditions such as intellectual disability and ASD that challenge differential diagnostic efforts. Therefore, using homogeneous genetic samples and implementing clearly defined DSM-based measures will allow for better understanding of true prevalence rates of ADHD in individuals with FXS. A differential diagnostic approach to known genetic and behaviorally similar neurodevelopmental disorders, specifically FXS and ADHD, can contribute to the field regarding diagnostic rates within FXS to allow for more targeted interventions that lead to increased independent living in this population.

The overall aims of the present study, therefore, were to (1) characterize the rate and presentation of ADHD diagnoses in youth with FXS using DSM-5 criteria, (2) determine the proportion of youth with FXS who were reported to have clinical ADHD symptoms on a widely-used parent rating scale, the Child Behavior Checklist (CBCL), as well as the concordance between CBCL symptom cut-offs and DSM-5 ADHD diagnoses; (3) determine the relationship between ASD symptom severity, nonverbal cognitive ability, and ADHD diagnoses and symptoms; and (4) describe the use of medication in relation to ADHD diagnostic status in youth with FXS. We hypothesized that >50% of the youth with FXS would meet criteria for a diagnosis of ADHD, with more individuals meeting for ADHD-I over the other two presentations. We expected moderate concordance between the CBCL ADHD scale and DSM-5 ADHD diagnoses given the concern that broad-based symptoms scales may lack specificity for individuals with intellectual disability and other comorbidities. We hypothesized that higher levels of ASD symptoms would be associated with ADHD diagnoses and symptoms given evidence for shared genetic mechanisms across ADHD and ASD (Ghirardi et al., 2019; Pinto et al., 2016; Ronald et al., 2008), but that lower nonverbal cognitive ability would not relate to ADHD, consistent with Newman et al. (2015). We expected that about half of participants would be using medications targeting ADHD symptoms, with stimulants being the most common medication type. We expected only moderate alignment between use of ADHD-targeted medications and ADHD diagnoses, considering prior evidence suggesting a high rate of stimulant medication use among individuals with FXS without an ADHD diagnosis (Valdovinos et al., 2009).

Method

Participants

Participants were 31 males with FXS ranging from 16-24 years of age ($M = 18.73$, $SD = 2.13$). Genetic testing was conducted on all participants to confirm the full mutation (>200 CGG repeats on 5'UTR of *FMR1*). Females were not included in the present study due to the heterogeneous phenotypic presentation of females with the FXS and the increased clinical involvement in males, which makes understanding of the extent, nature, and course of cooccurring challenges especially pressing for them (Bailey et al., 2008). Participants were drawn from a larger longitudinal multi-site study at the University of California at Davis and the University of South Carolina which focused on language development during the transition into adulthood (Abbeduto et al., 2019). Inclusionary criteria for the larger study required that English was the primary language, that the participants consistently used spontaneous two-to three-word utterances, and that they lived at home with their biological mother at study entry. Only individuals who participated at the University of South Carolina site were included in this study given a more focused interest on ADHD and the presence of sufficient resources at that site. Recruitment was conducted nationally through parent listservs, social media, postings by the National Fragile X Foundation, and with the help of the Research Participant Registry Core of the Carolina Institute for Developmental Disabilities at the University of North Carolina at Chapel Hill. The annual family incomes of the participants ranged from $<\$20,000$ to $>\$150,000$, with the median income reported at $\$80,000$. Ninety percent of participants were White, 7% were Black or African American, and 3% were Asian.

Procedures

The assessments included in the full protocol were conducted in a university laboratory setting and lasted two days. The measures for the present study are a subset of those administered. Data collection occurred based on established procedures of a larger study, including standardized order of test administration. Administration of the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2; Lord et al., 2012) was conducted on the morning of the second day of assessment to allow time for the participant to establish rapport with the examiner. Parent/caregiver report measures were completed by the participant's mother. All measures were completed at the second annual time point of the larger longitudinal study, except the ADOS-2, which was drawn from the first-year time point. ASD symptoms were only measured at study entry in the larger study given the relative stability of ASD symptoms in adolescents with FXS over time (Hernandez et al., 2009). Procedures were approved by the Institutional Review Board of the University of South Carolina and conform to the ethical standards laid out in the Declaration of Helsinki. All participants assented to participation, and informed consent was obtained from the participants' guardians.

Measures

Children's Interview for Psychiatric Syndromes—Parent version—(PChIPS; Fristad, Teare, Weller, Weller, & Salmon, 1998). The PChIPS is a DSM-based diagnostic interview that uses a strict diagnostic criteria model requiring the presence of impairment

to assess for the presence of ADHD symptoms and diagnosis. The PChIPS is a structured parent interview to assess presence of psychiatric disorders in children and adolescents aged 6-17 years old, which is consistent with the mental age of the participants enrolled in the present study. It queries symptom count, duration, and impairment consistent with DSM criteria. Questions pertaining to symptomology are presented and scored in a yes/no format. The current version of the PChIPS aligns with the DSM-IV; thus, we adapted the assessment to reflect the updated DSM-5 diagnostic criteria for ADHD, which required two modifications: (1) allowing for the concurrent diagnosis of ADHD and ASD, and (2) allowing a retrospective diagnosis to be made if five symptoms were present before age 12 years. Examiners were trained to administer the PChIPS by a licensed clinical psychologist. Inter-rater reliability for ADHD presentation classification was calculated on 20% of randomly selected samples. Percent agreement was 100% between the licensed psychologist and trained research staff. The categorical distinction of presence/absence of an ADHD disorder based on DSM-5 criteria served as the primary dependent variable in the analyses. The PChIPS has been applied to conditions associated with intellectual disability, including Phelan-McDermid syndrome (Shaw et al., 2011), FXS (Ezell et al., 2018), and ASD (Witwer & Lecavalier, 2010). High item-level agreement (intra-class correlation coefficients of 0.92 for Hyperactive, 0.97 for Inattentive, and 0.93 for Combined) and fair-to-moderate for diagnostic classification agreement (Hyperactive $\kappa = 0.43$, Inattentive $\kappa = 0.60$, and Combined $\kappa = 0.27$) has been reported between the PChIPS and the Child and Adolescent Symptom Inventory (CASI; Gadow & Sprafkin, 2002) in children with ASD (Witwer et al., 2012).

Attention Deficit/Hyperactivity Problems Scale, Child Behavior Checklist—(ADHD Scale, CBCL; Achenbach, 2001) was administered and is a widely used broad-based measure of child emotional and behavioral problems that provides an index of ADHD symptoms. The CBCL is a well-established 118-item parent-report tool that has good reliability and validity and has been widely used in neurodevelopmental disabilities research including FXS. The Attention Deficit/Hyperactivity Problems DSM-oriented subscale consists of 7-items and was designed to align with the symptoms of ADHD as outlined in the DSM. T-scores were computed and used to determine whether individual participants exceeded cut-offs for clinically significant ADHD symptoms; scores of 65-69 are considered “borderline clinical” and scores of 70+ are considered clinically significant. The 6-18 year old CBCL form for was used for all participants and 18-year norms were used to calculate standard scores for participants older than 18, consistent with prior work (Chromik et al., 2019; Roberts et al., 2019; Roberts et al., 2018). The 6-18 form was used for all participants because the items were thought to be more appropriate for the developmental level of young adults with FXS than is the adult form.

Autism Diagnostic Observation Schedule-Second Edition—(ADOS-2; Lord et al., 2012). The ADOS-2 was administered to determine ASD status and the severity of ASD symptoms. The ADOS-2 consists of a series of semi-structured interviews and play opportunities between an examiner and a participant, allowing for the observation of developmentally appropriate and inappropriate responses to these social exchanges. A continuous index of ASD symptoms, as reflected by the ADOS-2 calibrated severity

score, was also computed per the test instructions (Lord et al., 2012). Participants were administered the ADOS-2 module appropriate for their expressive language level and chronological age as specified by the administration manual, with modules 1, 2, and 3 represented in the present sample. The ADOS-2 was administered and scored live by graduate-level professionals who completed standard research reliability training. Ten percent of the administrations were randomly selected and second-scored by video for inter-reliability, with percent agreement above 80% across all items and algorithm items. Twenty-three participants (74.2%) exceeded the threshold for ASD.

Brief IQ, Leiter-R—(Roid & Miller, 1997). The Brief IQ of the Leiter-R is a nonverbal intelligence measure that has strong psychometric properties and is appropriate for use with individuals who have limited receptive and expressive language capabilities. Growth scale value scores, which reflect a transformation of raw scores into an equal-interval Rasch scale, were used in analysis to mitigate problems associated with floor effects in the standard scores.

Medications Targeting ADHD Symptoms.—Information on medication use was gathered as part of a standard demographic form for the larger study. The use of medications targeting ADHD symptoms was characterized as a bivariate present/absent variable. For the current study, any medication indicated by caregivers as targeting ADHD, attention, or hyperactivity was included (all such medications fell into the drug classes of stimulants or alpha-2 adrenergic agonists, such as guanfacine).

Statistical Analyses

Descriptive statistics were computed and are presented in Table 2. Variables were examined for normal distribution with no need for corrections indicated. A correlation matrix was computed to understand the relationship among variables to inform model specification (Table 3). Chronological age was not associated with the ADHD variables and, therefore, was not covaried in statistical models. To address the first research question regarding the rate and presentation of ADHD, the proportion of individuals who met DSM-5 diagnostic criteria for ADHD on the PChIPS was computed, as was the percentage of individuals meeting criteria for each ADHD presentation. The second research question was addressed by computing the percentage of individuals who obtained borderline or clinical scores on the CBCL ADHD scale. Cohen's kappa (κ ; Cohen, 1960), a measure of nominal scale agreement between two categorization of responses commonly used as a measure of classification accuracy (Kwiecien et al., 2011), was obtained to evaluate the concordance between DSM-5 ADHD diagnoses and the CBCL ADHD scale cut-offs. Concordance between the two measures was also examined descriptively by computing the percent of individuals who did/did not obtain borderline/clinical scores on the ADHD CBCL scale to those who did/did not meet diagnostic criteria for ADHD. Our third research question regarding the relationship between ASD symptom severity, nonverbal cognitive ability, and ADHD diagnoses and symptoms was tested by fitting two logistic regression models that included the ADOS-2 calibrated severity score and the Leiter-R growth scale value scores as predictors of either DSM-5 ADHD diagnoses or the CBCL ADHD subscale cut-off classification. Additionally, to test relationships with continuous ADHD symptoms,

a general linear model with fit to test the ADOS-2 calibrated severity score and the Leiter-R growth scale value as predictors of the CBCL ADHD subscale T-score. To address the final research question about medication use, the proportion of participants taking medications targeting ADHD symptoms was computed. All analyses were conducted using SAS software, version 9.4, (SAS Institute Inc., Cary, NC).

Results

Rate of DSM-5 ADHD Diagnoses and Presentations.

Thirteen of 31, or 41.9%, of the youth with FXS met DSM-5 diagnostic criteria for ADHD on the PChIPS. Of those who met criteria for ADHD, 69.2% (9/13) exhibited an ADHD-I presentation, 15.4% (2/13) exhibited an ADHD-H, and 15.4% (2/13) exhibited ADHD-C. See Figure 1.

Percent of Individuals Exceeding the CBCL ADHD Scale Cut-offs.

Ten of 31, or 32.3%, of the youth with FXS exceeded the CBCL ADHD cut-offs. Of these 10, 5 (16% of the total sample) obtained borderline scores and 5 (16% of the total sample) obtained scores in the clinical range.

Concordance Between DSM-5 ADHD Diagnosis and CBCL ADHD Cut-offs.

Cohen's kappa was calculated at $\kappa = 0.38$ (95% CI 0.06, 0.71), which is consistent with "fair" levels of agreement (Cohen, 1960). DSM-5 diagnoses and the CBCL ADHD scale cut-offs were concordant for 70.8% of the sample (22/31), see Table 4. Of those who met DSM-5 criteria for ADHD per the PChIPS clinical interview, 53.8% (7/13) also scored within the borderline or clinical range on the CBCL ADHD scale. The majority of individuals who did not meet diagnostic criteria for ADHD also obtained CBCL scores that were below cut-offs, 83.3% (15/18). DSM-5 diagnoses and the CBCL ADHD scale cut-offs were discordant for 29.0% of the sample: 19.4% met DSM-5 criteria for ADHD but did not score in the borderline/clinical range for ADHD on the CBCL, and 9.6% scored above CBCL cut-offs but did not meet DSM-5 criteria for ADHD.

ASD Symptom Severity and Nonverbal Cognitive Ability as Predictors of ADHD Diagnoses and Symptoms.

The results of the logistic regression model indicated that neither ASD symptom severity ($\chi^2 [1] = 0.02$, $p = .878$, $OR = 1.36$) nor nonverbal cognitive ability ($\chi^2 [1] = 1.74$, $p = .187$, $OR = 1.14$) were significant predictors of DSM-5 diagnostic criteria for ADHD on the PChIPS. Similarly, neither ASD symptom severity ($\chi^2 [1] = 0.43$, $p = .510$, $OR = 1.26$) nor nonverbal cognitive ability ($\chi^2 [1] = 0.72$, $p = .396$, $OR = 1.10$) were associated with increased odds of scoring above the cut-off for ADHD on the CBCL. Regression analyses also indicated that the combined influence of ASD symptom severity and nonverbal cognitive ability did not account for significant variance in continuous ADHD subscale T-scores on the CBCL, $F(2,28) = 0.05$, $p = 0.952$, $R^2 < 0.01$.

Frequency of Medication Use Targeting ADHD Symptoms.

Of the 31 individuals with FXS, 15 (48.4%) were taking medications that target ADHD symptoms. Nine of the 15 were taking stimulant medications. Of the 15 individuals using medications targeting ADHD symptoms, roughly half (53.3%, $n = 7$) met criteria for DSM-5 ADHD.

Discussion

FXS may serve as a saturated genetic model for ADHD, based on evidence of genetic overlap between intellectual disability, ASD, and ADHD, with prior research focused on children with FXS suggesting that ADHD is a highly prevalent and impairing cooccurring condition. Extending prior work focused on children, the present study investigated the rates, presentation, and correlates of ADHD in FXS during late adolescence and young adulthood, applying both DSM-5 diagnostic criteria as well as broadband parent rating scales. Forty-two percent of the adolescent and young-adult males with FXS in this study met DSM-5 criteria for ADHD, with neither intellectual disability nor ASD symptom severity predicting ADHD diagnostic outcome or symptoms. Concordance between DSM-5 diagnoses and cut-offs on the ADHD subscale of the CBCL was fair, yielding a concordant ADHD classification for 71% of the sample. Nearly half of the participants were using medications that target ADHD symptoms, although only half of those using ADHD medications met DSM-5 criteria for ADHD. Through inclusion of a relatively homogeneous sample of 16- to 24-year-old males with FXS, the majority of whom exhibited IQ scores consistent with moderate intellectual disability, this report describes for practitioners the expected rates of ADHD co-occurrence in this subpopulation and informs methods for evaluating ADHD for improved identification and access to interventions.

Elevated Rate and Presentation of ADHD in Adolescent/Young Adult Males with FXS

Prevalence rates of ADHD can vary greatly across diagnostic methods, necessitating focused study to clarify baseline rates of ADHD in individuals with FXS. The present study is the first to apply DSM-5 diagnostic criteria to determine ADHD diagnoses in adolescent and young adult males with FXS. Focused investigations of the adolescent/young adult period in FXS are critical as this developmental period tends to be marked by heightened psychopathological risk in the general population (Rutter, 2007).

Forty-two percent of the sample met criteria for ADHD, which is in line with previous diagnostic studies of children with FXS that have reported rates between 35-74% using earlier versions of the DSM (Backes et al., 2000; Sullivan et al., 2006). Therefore, our data support the notion that ADHD continues to represent a significant comorbidity in FXS into early adulthood, at rates that significantly exceed that of the general population. Although some previous research has suggested abatement of ADHD symptoms in FXS with age (Gabis et al., 2011; Wheeler et al., 2014), the results of the current study indicate that ADHD symptoms in adolescents and young adults exceed diagnostic thresholds at rates comparable to the rates that have been reported in children. It is possible that symptoms improve with age but continue to exceed diagnostic thresholds—a possibility that remains to

be addressed in future longitudinal work tracking intraindividual change in symptoms and diagnoses across time.

ADHD-I was the most prevalent ADHD presentation, with 29% of the sample exhibiting ADHD-I, 6% ADHD-H, and 6% ADHD-C. Rates of the ADHD presentations align with previous research employing DSM-IV criteria in younger and/or more heterogeneous samples. Sullivan et al. (2006) also observed ADHD-I as the dominant presentation in a sample of 7-13 year-old boys and girls with FXS ($n = 57$); ADHD-I was observed in 32% the sample, ADHD-I in 7%, and ADHD-C in 15%. Similarly, Gabis et al. (2011) detected ADHD-I in 27%, ADHD-H in 13%, and ADHD-C in 7% of an older but smaller sample of 15 males and females with FXS, aged 12-29 years. Corroborating and building these earlier reports using DSM-5 criteria in a more homogeneous sample of males aged 16-24 years, we found that ADHD in adolescent and young adult males with FXS is overwhelmingly characterized by the inattentive symptoms (69% of those who met criteria for ADHD exhibited ADHD-I, and an additional 15% met criteria for ADHD-C). Characterizing ADHD presentation within FXS is of relevance because those presentations are associated with different clinical needs. Relative to ADHD-H, children with ADHD-I are more likely to show social isolation, experience comorbid anxiety and depression, and experience learning and reading difficulties (Baeyens et al., 2006; Paloyelis et al., 2010; Willcutt et al., 2001; Willcutt et al., 2007). In clinical samples, hyperactivity/impulsivity symptoms also tend to improve with age, whereas inattention symptoms are more likely to persist across development (Hurtig et al., 2007).

No Association With Nonverbal Cognitive Ability or ASD Symptoms

We did not detect an association between ASD symptom severity and ADHD diagnoses or symptoms. Findings on the relations between ASD symptoms/comorbidity and attention problems in children with FXS have been conflicting, with differences in the samples and methodologies making it difficult to tease apart the source of discrepancies across reports. Some cross-sectional reports have not detected a relationship between ADHD and ASD symptoms in FXS (Hatton et al., 2002; Newman et al., 2015) and emerging longitudinal evidence suggests that clinical ADHD symptoms in school-aged boys with FXS remain high and stable across time regardless of whether cooccurring ASD features are also present (Cornish et al., 2013). In contrast, other studies have reported association between ADHD and ASD symptoms in individuals with FXS (Doherty et al., 2020; Smith et al., 2012). In this report, we did not find evidence that ASD symptoms translated to heightened ADHD symptoms or higher likelihood of an ADHD diagnosis in adolescents and young adults with FXS.

Nonverbal cognitive ability was not associated with ADHD symptoms or diagnoses, which aligns with the findings of Newman et al. (2015). Understanding the relationship between ADHD and intellectual disability within the context of FXS, or the lack thereof, has implications for diagnostic practices with regard to the phenomenon of diagnostic overshadowing (e.g., when intellectual disability “overshadows” the presence of comorbid conditions such as ADHD, leading to reduced clinical recognition and treatment of concomitant disorders; Mason & Scior, 2004; White et al., 1995). In the present study,

ADHD symptoms and diagnoses were not related to differences in IQ, which lends validity to the ADHD diagnosis in FXS and highlights the need for caution when conceptualizing ADHD symptoms in this group as features that are inherent to the presence of intellectual disability. The identification of ADHD in individuals with FXS is critical to facilitating access to interventions that have the potential to improve quality of life.

Implications for the Assessment of ADHD Within Individuals With FXS

This report provides broad support for the utility of the PChIPS for use in FXS, while also underscoring the need for further formal psychometric investigation to validate the PChIPS for use in intellectual and developmental disabilities. Several investigations have now successfully applied the PChIPS to characterize mental health disorders in children with various forms of intellectual and developmental disabilities (Ezell et al., 2018; Shaw et al., 2011; Witwer & Lecavalier, 2010), including a psychometric study by Witwer et al. (2012) that found good reliability and support for concurrent validity when applying the PChIPS to a sample of children with ASD. Interestingly, the PChIPS showed excellent agreement with the CASI for item-level ADHD symptoms, while concordance between the two measures for ADHD diagnostic outcome was only fair. Witwer et al. (2012) speculated that diagnostic discrepancies may have been related to the challenges of capturing impairment associated with ADHD within a population that also experiences concomitant behavioral difficulties related to ASD (i.e., caregivers may be less reliable in recognizing and endorsing ADHD-related impairment when their child experiences pervasive impairment related to other cooccurring conditions). Notably, however, the PChIPS and CASI were not more discordant in subgroups of children with ASD with IQs above or below 70, suggesting that the PChIPS performed equivocally in children with and without cooccurring intellectual disability (Witwer et al., 2012). While more psychometric work is needed, the present report builds on evidence that the PChIPS can be successfully applied to populations with intellectual disability.

The present study also has implications for the use of the CBCL to characterize ADHD in FXS. The CBCL is a widely-used broadband symptom scale that shows moderate sensitivity and specificity for identifying ADHD in clinical and community settings (Chang et al., 2016). However, the CBCL has also been suggested to lack specificity for individuals with co-occurring disorders (Pandolfi et al., 2012) and, therefore, may result in overestimation of ADHD rates in FXS relative. We found that the Kappa classification agreement between the CBCL ADHD cut-offs and DSM-5 diagnoses determined via the PChIPS were only fair in this sample of adolescents and young adults with FXS. The CBCL missed 19% of those who met DSM-5 criteria for ADHD. Compared to the 42% rate of ADHD determined via the DSM-5, 32% of the sample exceeded the CBCL cut-off scores for ADHD when considering both borderline and clinical scores as elevated. When only clinical CBCL scores were considered, just 16% of the sample exceeded cut-offs. These findings closely mirror the results of Sullivan et al.'s (2006) study of children with FXS in which only 6% of the sample exceeded CBCL ADHD clinical cut-offs, compared to 53% when parents completed a DSM-IV-based ADHD symptom inventory. Together, these findings suggest under-identification of ADHD in FXS via the CBCL, rather than over-identification. Therefore, caution should be exercised when relying on the CBCL to characterize ADHD

in individuals with FXS; the use of a DSM-based ADHD-specific interview/symptom inventory appears to improve identification accuracy. When employing the CBCL, both borderline and clinical scores should be considered, as reliance on only the clinical scores resulted in gross underestimation of ADHD rates in both the present study and in the Sullivan et al. (2006) report.

Medication Use

Nearly half of the adolescents and young adults in this study were using ADHD-targeted medications, which is similar to rates of medication usage found in previous research (Roberts et al., 2011a). Stimulants were the most commonly used drug class to target ADHD, which is notable given that stimulants are poorly tolerated in FXS—they represent the psychotropic medication that is most likely to be discontinued, with common side effects of anxiety, irritability, and mood lability (Berry-Kravis & Potanos, 2004; Valdovinos et al., 2009). Interestingly, about half of the participants who were using ADHD-targeted medications did not meet diagnostic criteria for ADHD. The reason for this is unclear, although it could reflect use of stimulant medications in individuals with FXS who display some subthreshold symptoms of ADHD. It is also possible that ADHD-targeted medications were prescribed to treat symptoms other than ADHD; for example, a nation-wide survey by Valdovinos et al. (2009) found surprisingly high rates of stimulant use in individuals with FXS who had difficulty with anxiety. Although medication is typically the first course of intervention for individuals with FXS who exhibit ADHD, future research should examine the utility of a combined pharmaceutical and behavioral approach, as this approach is typically most effective in the management of ADHD outside of the context of FXS (Parens & Johnston, 2009; Pelham et al., 2000).

Strengths, Limitations, and Directions

Strengths of the present study include the narrow, well-defined sample of individuals with FXS, who were all males with intellectual disability falling between the ages of 16- to 21 years. Although a trade-off to the inclusion of such a homogenous sample was a more limited sample size of 31 individuals, the focused sample clarifies the expected ADHD profile in males with FXS during adolescence and young adulthood, specifically. The use of a DSM-based diagnostic interview to evaluate the presences of ADHD is also a strength, and this is the first report to apply the new DSM-5 criteria to a FXS sample.

There are a number of measurement considerations. First, our multimethod approach incorporating both the PChIPS and the CBCL is a strength. However, it should be acknowledged that differential diagnosis of ADHD in a clinical setting would involve multiple sources of information (parent and teacher report data, behavioral measures, etc) paired with professional clinical judgement. Therefore, our determination of ADHD status is still limited relative to a thorough clinical evaluation. Additionally, our use of parent report can be viewed as a limitation as parent perceptions of impairment can be skewed due to the significant level of impairment in children with intellectual disability and particularly individuals with FXS. However, self-reported behaviors were not an option in this FXS sample due to intellectual disability and low language skills. Future studies pairing parent-report data with clinical observation or teacher-report data may help mitigate rater biases.

Another limitation was our use of the CBCL 6-18 form for all participants; 13 participants were above the age range of the norming sample. Although this approach is consistent with prior work (Chromik et al., 2019; Roberts et al., 2019; Roberts et al., 2018) and appropriate given the developmental level of the participants, it should be acknowledged that the standard scores for the older participants may have decreased validity.

Conclusions

ADHD continues to represent a significant comorbidity in FXS through the adolescent and young adult years, with 42% of 16- to 21-year-old males in the present study meeting DSM-5 criteria for ADHD. Evaluation of ADHD via the CBCL yielded lower rates of ADHD and classification agreement between the DSM-5 and CBCL ADHD subscale was only fair, suggesting that overreliance on the CBCL may result in under-characterization of ADHD symptoms in FXS. ADHD diagnoses and symptoms were not predicted by low IQ or the presence of ASD symptoms in this sample of males with FXS, which has implications for the phenomenon of “diagnostic overshadowing,” or the clinical tendency to overlook comorbid conditions in the presence of intellectual disability. This report describes for practitioners the expected rates of ADHD in adolescent and young adult males with FXS and ADHD measurement in this group, in efforts to facilitating access to interventions and improve quality of life.

Acknowledgments

This research was funded by the National Institutes of Health, Grant/Award Numbers R01HD024356 and P50HD103526 awarded to Leonard Abbeduto, R21DC017804 and R03HD098291 awarded to Jessica Klusek, and the Research Participant Registry Core of the Carolina Institute for Developmental Disabilities (U54HD079124). We extend our gratitude to the individuals who participated in this research and their families.

References

- Abbeduto L, Thurman AJ, McDuffie A, Klusek J, Feigles RT, Brown WT, Harvey DJ, Adayev T, LaFauci G, & Dobkins C (2019). ASD comorbidity in fragile X syndrome: symptom profile and predictors of symptom severity in adolescent and young adult males. *Journal of Autism and Developmental Disorders*, 49(3), 960–977. [PubMed: 30382442]
- Achenbach TM (2001). *Child behavior checklist for ages 6 to 18*. University of Vermont, Research Center for Children, Youth, and Families.
- Aman MG, Singh NN, Stewart AW, & Field CJ (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. *American Journal of Mental Deficiency*, 89, 485–491. [PubMed: 3993694]
- American Psychiatric Association. (1980). *Diagnostic and Statistical Manual of Mental Disorders* (3rd ed.). American Psychiatric Association.
- American Psychiatric Association. (2000). *Diagnostic and Statistical Manual of Mental Disorders* (4th ed., text revision). American Psychiatric Association.
- American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.; DSM-5 ed.). American Psychiatric Publishing, Incorporated.
- Backes M, Genc B, Schreck J, Doerfler W, Lehmkühl G, & Von Gontard A (2000). Cognitive and behavioral profile of fragile X boys: correlations to molecular data. *American Journal of Medical Genetics*, 95(2), 150–156. [PubMed: 11078566]
- Baeyens D, Roeyers H, & Walle JV (2006). Subtypes of attention-deficit/hyperactivity disorder (ADHD): distinct or related disorders across measurement levels? *Child Psychiatry and Human Development*, 36(4), 403–417. [PubMed: 16755403]

- Bailey DB, Raspa M, Olmsted M, & Holiday DB (2008). Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. *American Journal of Medical Genetics: Part A*, 146A, 2060–2069. [PubMed: 18570292]
- Barkley RA, Fischer M, Smallish L, & Fletcher K (2004). Young adult follow-up of hyperactive children: antisocial activities and drug use. *Journal of Child Psychology and Psychiatry*, 45(2), 195–211. [PubMed: 14982236]
- Baumgardner TL, Reiss AL, Freund LS, & Abrams MT (1995). Specification of the neurobehavioral phenotype in males with fragile X syndrome. *Pediatrics*, 95(5), 744–752. [PubMed: 7724315]
- Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, & Urv TK (2013). Outcome measure for clinical trials in fragile X syndrome. *Journal of Developmental and Behavioral Pediatrics*, 34(7), 508–522. [PubMed: 24042082]
- Berry-Kravis E, & Potanos K (2004). Psychopharmacology in fragile X syndrome--present and future. *Mental retardation and developmental disabilities research reviews*, 10(1), 42–48. [PubMed: 14994287]
- Berry-Kravis E, Sumis A, Hervey C, & Mathur S (2012). Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. *International Journal of Pediatrics*, 2012, Article ID 843016. [PubMed: 22899942]
- Biederman J, Petty CR, Evans M, Small J, & Faraone SV (2010). How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. *Psychiatry Research*, 177(3), 299–304. [PubMed: 20452063]
- Bregman JD, Leckman JF, & Ort SI (1988). Fragile X syndrome: Genetic Predisposition of psychopathy. *Journal of Autism and Developmental Disorders*, 18, 343–354. [PubMed: 3170453]
- Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, & Kaufmann WE (2017). Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. *Journal of Neurodevelopmental Disorders*, 9(1), 14. [PubMed: 28616097]
- Chang L-Y, Wang M-Y, & Tsai P-S (2016). Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: A meta-analysis. *Pediatrics*, 137(3).
- Chromik LC, Quintin E-M, Lepage J-F, Hustyi KM, Lightbody AA, & Reiss AL (2019). The influence of hyperactivity, impulsivity, and attention problems on social functioning in adolescents and young adults with fragile X syndrome. *Journal of attention disorders*, 23(2), 181–188. [PubMed: 25731183]
- Cohen J (1960). A Coefficient of Agreement for Nominal Scales. *Educational and Psychological Measurement*, 20(1), 37–46.
- Conners CK (1997). *Conners' Teacher Rating Scale--Revised*. Multi-Health Systems North Tonawanda, NY.
- Conners CK (2008). *Conners third edition (Conners 3)*. Los Angeles, CA: Western Psychological Services.
- Conners CK (2009). *Conners Early Childhood*. Multi-Health Systems Inc.
- Cornish K, Cole V, Longhi E, Karmiloff-Smith A, & Scerif G (2013). Do behavioural inattention and hyperactivity exacerbate cognitive difficulties associated with autistic symptoms? Longitudinal profiles in fragile X syndrome. *International Journal of Developmental Disabilities*, 59(2), 80–94.
- Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, & Blumberg SJ (2018). Prevalence of parent-reported ADHD diagnosis and associated treatment among US children and adolescents, 2016. *Journal of Clinical Child and Adolescent Psychology*, 47(2), 199–212. [PubMed: 29363986]
- Doherty BR, Longhi E, Cole V, Karmiloff-Smith A, Cornish K, & Scerif G (2020). Disentangling autism spectrum and attention-deficit/hyperactivity symptoms over development in fragile X syndrome. *Research in Developmental Disabilities*, 104, 103692. [PubMed: 32505083]
- Ezell J, Hogan A, Fairchild A, Hills K, Klusek J, Abbeduto L, & Roberts J (2018). Prevalence and predictors of anxiety disorders in adolescent and adult males with autism spectrum disorder and fragile X syndrome. *Journal of Autism and Developmental Disorders*, 1–11. [PubMed: 28864932]
- Faraone SV, Ghirardi L, Kuja-Halkola R, Lichtenstein P, & Larsson H (2017). The Familial Co-Aggregation of Attention-Deficit/Hyperactivity Disorder and Intellectual Disability: A Register-

- Based Family Study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 56(2), 167–174.e161. [PubMed: 28117063]
- Freund LS, & Reiss AL (1991). Cognitive profiles associated with the fra(X) syndrome in males and females
- Freund LS, Reiss AL, & Abrams MT (1993). Psychiatric disorders associated with fragile X in the young female. *Pediatrics*, 91(2), 321–329. [PubMed: 8380924]
- Frolli A, Piscopo S, & Conson M (2015). Developmental changes in cognitive and behavioural functioning of adolescents with fragile-X syndrome. *Journal of Intellectual Disability Research*, 59(7), 613–621. [PubMed: 25160119]
- Gabis LV, Baruch YK, Jokel A, & Raz R (2011). Psychiatric and autistic comorbidity in fragile X syndrome across ages. *Journal of Child Neurology*, 26(8), 940–948. [PubMed: 21527394]
- Gadow KD, & Sprafkin J (1997). *Child Symptom Inventory 4: CSI. Checkmate Plus* Stony Brook, NY.
- Gadow KD, Sprafkin J, Attack P, Phobia S, Tics DM, & Anorexia D (1997). *Adolescent symptom inventory-4 (ASI-4)*. Stony Brook, NY: Checkmate Plus.
- Gadow KD, & Sprafkin JN (2002). *Child Symptom Inventory 4: Screening and norms manual*. Checkmate Plus.
- Ghirardi L, Brikell I, Kuja-Halkola R, Freitag CM, Franke B, Asherson P, Lichtenstein P, & Larsson H (2018). The familial co-aggregation of ASD and ADHD: a register-based cohort study. *Molecular Psychiatry*, 23(2), 257–262. [PubMed: 28242872]
- Ghirardi L, Pettersson E, Taylor MJ, Freitag CM, Franke B, Asherson P, Larsson H, & Kuja-Halkola R (2019). Genetic and environmental contribution to the overlap between ADHD and ASD trait dimensions in young adults: a twin study. *Psychological Medicine*, 49(10), 1713–1721. [PubMed: 30191778]
- Grefer M, Flory K, Cornish K, Hatton D, & Roberts J (2016). The emergence and stability of attention deficit hyperactivity disorder in boys with fragile X syndrome. *Journal of Intellectual Disability Research*, 60(2), 167–178. [PubMed: 26610738]
- Haessler F, Gaese F, Huss M, Kretschmar C, Brinkman M, Peters H, Elstner S, Colla M, & Pittrow D (2016). Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study. *BMC Psychiatry*, 16(1), 318. [PubMed: 27612457]
- Hagerman RJ, Murphy MA, & Wittenberger MD (1988). A controlled trial of stimulant medication in children with the fragile X syndrome. *American Journal of Medical Genetics*, 30(1-2), 377–392. [PubMed: 3052064]
- Harpin V, Mazzone L, Raynaud J, Kahle J, & Hodgkins P (2016). Long-term outcomes of ADHD: a systematic review of self-esteem and social function. *Journal of attention disorders*, 20(4), 295–305. [PubMed: 23698916]
- Hatton DD, Hooper SR, Bailey DB, Skinner ML, Sullivan KM, & Wheeler A (2002). Problem behavior in boys with fragile X syndrome. *American Journal of Medical Genetics*, 108(2), 105–116. [PubMed: 11857559]
- Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, & Kaufmann WE (2009). Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation. *American Journal of Medical Genetics Part A*, 149(6), 1125–1137.
- Hinshaw SP, Owens EB, Zalecki C, Huggins SP, Montenegro-Nevado AJ, Schrodek E, & Swanson EN (2012). Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: Continuing impairment includes elevated risk for suicide attempts and self-injury. *Journal of Consulting and Clinical Psychology*, 80(6), 1041. [PubMed: 22889337]
- Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, & Leal J (2014). Epidemiology of fragile X syndrome: A systematic review and meta-analysis. *American Journal of Medical Genetics Part A*, 164(7), 1648–1658.
- Hurtig T, Ebeling H, Taanila A, Miettunen J, Smalley SL, McGOUGH JJ, Loo SK, Järvelin M-R, & Moilanen IK (2007). ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms. *Journal of the American Academy of Child and Adolescent Psychiatry*, 46(12), 1605–1613. [PubMed: 18030082]

- Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, & Secnik K (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. *American Journal of Psychiatry*, 163(4), 716–723. [PubMed: 16585449]
- Kuriyan AB, Pelham WE, Molina BS, Waschbusch DA, Gnagy EM, Sibley MH, Babinski DE, Walther C, Cheong J, & Yu J (2013). Young adult educational and vocational outcomes of children diagnosed with ADHD. *Journal of Abnormal Child Psychology*, 41(1), 27–41. [PubMed: 22752720]
- Kwicien R, Kopp-Schneider A, & Blettner M (2011). Concordance analysis: part 16 of a series on evaluation of scientific publications. *Deutsches Arzteblatt international*, 108(30), 515–521. [PubMed: 21904584]
- Li Z, Chang S. h., Zhang L. y., Gao L, & Wang J (2014). Molecular genetic studies of ADHD and its candidate genes: a review. *Psychiatry Research*, 219(1), 10–24. [PubMed: 24863865]
- Loe IM, & Feldman HM (2007). Academic and educational outcomes of children with ADHD. *Journal of Pediatric Psychology*, 32(6), 643–654. [PubMed: 17569716]
- Margherio SM, Capps ER, Monopoli JW, Evans SW, Hernandez-Rodriguez M, Owens JS, & DuPaul GJ (2020). Romantic relationships and sexual behavior among adolescents with ADHD. *Journal of attention disorders*, 1087054720914371.
- Mason J, & Scior K (2004). ‘Diagnostic overshadowing’ amongst clinicians working with people with intellectual disabilities in the UK. *Journal of Applied Research in Intellectual Disabilities*, 17(2), 85–90.
- May T, Brignell A, Hawi Z, Brereton A, Tonge B, Bellgrove M, & Rinehart N (2018). Trends in the overlap of autism spectrum disorder and attention deficit hyperactivity disorder: prevalence, clinical management, language and genetics. *Current Developmental Disorders Reports*, 5(1), 49–57.
- Molina BS, Howard AL, Swanson JM, Stehli A, Mitchell JT, Kennedy TM, Epstein JN, Arnold LE, Hechtman L, & Vitiello B (2018). Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study. *Journal of Child Psychology and Psychiatry*, 59(6), 692–702. [PubMed: 29315559]
- Newman I, Leader G, Chen JL, & Mannion A (2015). An analysis of challenging behavior, comorbid psychopathology, and Attention-Deficit/Hyperactivity Disorder in Fragile X Syndrome. *Research in Developmental Disabilities*, 38, 7–17. [PubMed: 25543996]
- Paloyelis Y, Rijdsdijk F, Wood AC, Asherson P, & Kuntsi J (2010). The genetic association between ADHD symptoms and reading difficulties: the role of inattentiveness and IQ. *Journal of Abnormal Child Psychology*, 38(8), 1083–1095. [PubMed: 20556504]
- Pandolfi V, Magyar CI, & Dill CA (2012). An initial psychometric evaluation of the CBCL 6–18 in a sample of youth with autism spectrum disorders. *Research in Autism Spectrum Disorders*, 6(1), 96–108. [PubMed: 22059091]
- Parens E, & Johnston J (2009). Facts, values, and Attention-Deficit Hyperactivity Disorder (ADHD): an update on the controversies. *Child and Adolescent Psychiatry and Mental Health*, 3(1), 1. [PubMed: 19152690]
- Pegoraro LF, Steiner CE, Celeri EH, Banzato CE, & Dalgarrondo P (2014). Cognitive and behavioral heterogeneity in genetic syndromes. *Jornal de Pediatria*, 90(2), 155–160. [PubMed: 24184301]
- Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, & Baron-Myak C (2000). Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. *Journal of Abnormal Child Psychology*, 28(6), 507–525. [PubMed: 11104314]
- Pinto R, Rijdsdijk F, Ronald A, Asherson P, & Kuntsi J (2016). The genetic overlap of attention-deficit/hyperactivity disorder and autistic-like traits: An investigation of individual symptom scales and cognitive markers. *Journal of Abnormal Child Psychology*, 44(2), 335–345. [PubMed: 26021462]
- Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP, Termine C, Bonati M, & Group LA (2017). Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. *European Child and Adolescent Psychiatry*, 26(12), 1443–1457. [PubMed: 28527021]

- Reich W (2000). Diagnostic interview for children and adolescents (DICA). *Journal of the American Academy of Child and Adolescent Psychiatry*, 39(1), 59–66. [PubMed: 10638068]
- Reilly C, Senior J, & Murtagh L (2015). ASD, ADHD, mental health conditions and psychopharmacology in neurogenetic syndromes: parent survey. *Journal of Intellectual Disability Research*, 59(4), 307–318. [PubMed: 24965264]
- Roberts J, Crawford H, Hogan AL, Fairchild A, Tonnsen B, Brewe A, O'Connor S, Roberts DA, & Abbeduto L (2019). Social avoidance emerges in infancy and persists into adulthood in fragile X syndrome. *Journal of Autism and Developmental Disorders*, 49(9), 3753–3766. [PubMed: 31165359]
- Roberts J, Miranda M, Boccia M, Janes H, Tonnsen B, & Hatton D (2011a). Treatment effects of stimulant medication in young boys with fragile X syndrome. *Journal of Neurodevelopmental Disorders*, 3(3), 175–184. [PubMed: 21671049]
- Roberts JE, Ezell JE, Fairchild AJ, Klusek J, Thurman AJ, McDuffie A, & Abbeduto L (2018). Biobehavioral composite of social aspects of anxiety in young adults with fragile X syndrome contrasted to autism spectrum disorder. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*.
- Roberts JE, Miranda M, Boccia M, Janes H, Tonnsen BL, & Hatton DD (2011b). Treatment effects of stimulant medication in young boys with fragile X syndrome. *Journal of Neurodevelopmental Disorders*, 3(3), 175–184. [PubMed: 21671049]
- Roid GH, & Miller LJ (1997). *Leiter International Performance Scale-Revised*. Stoelting.
- Ronald A, Simonoff E, Kuntsi J, Asherson P, & Plomin R (2008). Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. *Journal of Child Psychology and Psychiatry*, 49(5), 535–542. [PubMed: 18221348]
- Rutter M (2007). Psychopathological development across adolescence. *Journal of youth and adolescence*, 36(1), 101–110.
- Scerif G, Longhi E, Cole V, Karmiloff-Smith A, & Cornish K (2012). Attention across modalities as a longitudinal predictor of early outcomes: the case of fragile X syndrome. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, 53(6), 641–650. [PubMed: 22211574]
- Schneider S, Unnewehr S, & Margraf J (1995). *Kinder-DIPS*. Berlin, Springer.
- Shaw SR, Rahman A, & Sharma A (2011). Behavioral profiles in Phelan-McDermid syndrome: Focus on mental health. *Journal of Mental Health Research in Intellectual Disabilities*, 4(1), 1–18.
- Siegel JJ, Chitwood RA, Ding JM, Payne C, Taylor W, Gray R, Zemelman BV, & Johnston D (2017). Prefrontal cortex dysfunction in fragile X mice depends on the continued absence of fragile X mental retardation protein in the adult brain. *Journal of Neuroscience*, 37(31), 7305–7317. [PubMed: 28652410]
- Smith LE, Barker ET, Seltzer MM, Abbeduto L, & Greenberg JS (2012). Behavioral phenotype of fragile X syndrome in adolescence and adulthood. *American Journal on Intellectual and Developmental Disabilities*, 117(1), 1–17. [PubMed: 22264109]
- Stergiakouli E, Hamshere M, Holmans P, Langley K, Zaharieva I, Genetics, d., Subgroup, P. G. C. A., Hawi Z, Kent L, & Gill M (2012). Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. *American Journal of Psychiatry*, 169(2), 186–194. [PubMed: 22420046]
- Stergiakouli E, Smith GD, Martin J, Skuse DH, Viechtbauer W, Ring SM, Ronald A, Evans DE, Fisher SE, & Thapar A (2017). Shared genetic influences between dimensional ASD and ADHD symptoms during child and adolescent development. *Molecular Autism*, 8(1), 18. [PubMed: 28392908]
- Sullivan K, Hatton D, Hammer J, Sideris J, Hooper S, Ornstein P, & Bailey D Jr (2006). ADHD symptoms in children with FXS. *American Journal of Medical Genetics Part A*, 140(21), 2275–2288. [PubMed: 17022076]
- Thurman AJ, McDuffie A, Hagerman R, & Abbeduto L (2014). Psychiatric symptoms in boys with fragile X syndrome: A comparison with nonsyndromic autism spectrum disorder. *Research in Developmental Disabilities*, 35(5), 1072–1086. [PubMed: 24629733]

- Valdovinos M, Parsa R, & Alexander M (2009). Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome. *Journal of Developmental and Physical Disabilities*, 21(1), 23–37.
- Vissers LE, Gilissen C, & Veltman JA (2016). Genetic studies in intellectual disability and related disorders. *Nature Reviews Genetics*, 17(1), 9–18.
- Waye MM, & Cheng HY (2018). Genetics and epigenetics of autism: A Review. *Psychiatry and Clinical Neurosciences*, 72(4), 228–244. [PubMed: 28941239]
- Wheeler A, Raspa M, Bann C, Bishop E, Hessel D, Sacco P, & Bailey DB Jr (2014). Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome. *American Journal of Medical Genetics Part A*, 164(1), 141–155.
- White MJ, Nichols CN, Cook RS, & Spengler PM (1995). Diagnostic overshadowing and mental retardation: A meta-analysis. *American Journal on Mental Retardation*.
- Willcutt EG, Pennington BF, Boada R, Ogline JS, Tunick RA, & Chhabildas NA (2001). A comparison of the cognitive deficits in reading disability and attention deficit/hyperactivity disorder. *Journal of Abnormal Child Psychology*, 110, 157–172.
- Willcutt EG, Pennington BF, Olson RK, & DeFries JC (2007). Understanding comorbidity: A twin study of reading disability and attention-deficit/hyperactivity disorder. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 144(6), 709–714.
- Witwer AN, & Lecavalier L (2010). Validity of comorbid psychiatric disorders in youngsters with autism spectrum disorders. *Journal of Developmental and Physical Disabilities*, 22(4), 367–380.
- Witwer AN, Lecavalier L, & Norris M (2012). Reliability and Validity of the Children’s Interview for Psychiatric Syndromes-Parent Version in Autism Spectrum Disorders. *Journal of Autism and Developmental Disorders*, 42(9), 1949–1958. [PubMed: 22274777]
- Zhang K, Li Y. j., Guo Y, Zheng K. y., Yang Q, Yang L, Wang X. s., Song Q, Chen T, & Zhuo M (2017). Elevated progranulin contributes to synaptic and learning deficit due to loss of fragile X mental retardation protein. *Brain*, 140(12), 3215–3232. [PubMed: 29096020]




Figure 1.
Percent of Youth with FXS Meeting Criteria for ADHD

Table 1

Reported Rates of ADHD in Individuals with FXS

Authors (Year)	<i>n</i>	Age	Sex (M:F)	Measure	Rate of ADHD
Studies Utilizing Diagnostic Indices of ADHD					
Backes, Genç, Schreck, Doerfler, Lehmkühl, & Von Gontard (2000)	49	5 – 16 years (<i>M</i> = 9 years)	49:0	Kinder-DIPS ^a	74%
Baumgardner, Reiss, Freund, & Abrams (1995)	31	3 – 18 years (<i>M</i> = 8 years)	31:0	DSM -III ^b	73%
Freund, Reiss, & Abrams (1993)	17	4 – 27 years	0:17	Diagnostic Interview for Children and Adolescents (DICA)-Parent Version ^c	35%
Pegoraro, Steiner, Celeri, Banzato & Dalgalarondo (2014)	13	6 – 16 years (<i>M</i> = 12 years)	12:1	DSM-IV-TR ^d	77%
Sullivan, Hatton, Hammer, Sideris, Hooper, Ornstein, & Bailey (2006)	59	7 – 13 years (<i>M</i> = 10 years)	54:5	Childhood Symptom Inventory-4 (CSI-4), Parent Checklist ^e or Adolescent Symptom Inventory -4 (ASI-4), Parent Checklist ^f	54%
				Childhood Symptom Inventory-4 (CSI-4), Teacher Checklist ^e or Adolescent Symptom Inventory -4 (ASI-4), Teacher Checklist ^f	59%
Studies Utilizing Screening/Symptom Rating Scale Indices of ADHD					
Baumgardner, Reiss, Freund, & Abrams (1995)	31	3 – 18 years (<i>M</i> = 8 years)	31:0	Aberrant Behavior Checklist (ABC) Hyperactivity Scale, Parent Report ^g	40%
				Aberrant Behavior Checklist (ABC) Hyperactivity Scale, Teacher Report ^g	50%
Cornish, Cole, Longhi, Karmiloff-Smith, & Scerif (2013)	46	58 – 133 months (<i>M</i> = 9 years)	46:0	Conner's Teacher Rating Scale – Revised: Short Form ^h	43%
Grefer, Flory, Cornish, Hatton, & Roberts (2016)	33	36 – 55 months (<i>M</i> = 41 months)	33:0	CBCL Attention/Hyperactivity DSM-oriented Subscale, Parent Report Form ⁱ (reported rate does not include borderline scores)	9%
Hatton, Hooper, Bailey, Skinner, Sullivan, & Wheeler (2002)	59	48 - 152 months (<i>M</i> = 87 months)	59:0	CBCL Attention Problems Subscale, Parent Report Form ^j (reported rate includes borderline scores)	56%
Newman, Leader, Chen, & Mannion (2015)	47	2 – 17 years (<i>M</i> = 8 years)	35:12	Conners-3 Inattention and Hyperactivity/Impulsivity Subscales, Parent Short Version ^j & Conners Early Childhood, Parent Short Version ^k	83%

Note.

^a Schneider et al. (1995)^b American Psychiatric Association (1980)^c Reich (2000)^d American Psychiatric Association (2000)^e Gadow and Sprafkin (1997)

^f Gadow et al. (1997)

^g Aman et al. (1985)

^h Conners (1997)

ⁱ Achenbach (2001)

^j Conners (2008)

^k Conners (2009)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Descriptive Statistics

Variable	<i>M</i> (<i>SD</i>) Range
Brief IQ Standard Score, Leiter-R	38.97 (5.39) 36.00-56.00
Brief IQ Growth Scale Value, Leiter-R	459.90 (14.27) 420.00-488.00
ASD Severity Score, ADOS-2	5.68 (2.31) 1.00-10.00
ADHD Scale T Score, CBCL	58.87 (2.13) 50.0-73.0

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Correlation Matrix

	DSM-5 ADHD Diagnosis	ADHD Scale T Score, CBCL	ASD Severity Score, ADOS-2	Brief IQ Growth Scale Value, Leiter-R	Chronological Age
DSM-5 ADHD Diagnosis	---	.40*	-.11	.27	.07
ADHD Scale T Score, CBCL		---	-.01	.06	.12
ASD Severity Score, ADOS-2			---	-.31	-.16
Brief IQ Growth Scale Value Score, Leiter-R				---	.43*
Chronological Age					---

*
 $p < .050$

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4

Number of Individuals Meeting Criteria for a DSM-5 ADHD Diagnosis in Comparison to CBCL ADHD Cut-offs

Range of CBCL ADHD Scale T-Score	DSM-5 ADHD Diagnosis	
	Positive (n)	Negative (n)
<i>Clinical</i>	4	1
<i>Borderline</i>	3	2
<i>Normal</i>	6	15
Total	13	18

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript